Melola Discovery

← Melola Discovery

Jurnal SINTA 1

FEV1-Reversibility in House-Dust Immunotherapy Compared with Inhaled Corticosteroid in The Treatment of Childhood Asthma

Folia Medica Indonesiana · Vol. 42 No. 1 (2006)

ISSN
2355-8393, 2599-056X
Terbit
2006-01-01
Penerbit
Airlangga University
Bahasa
en

Abstrak

Asthma is a chronic inflammatory disease of the airway. Corticosteroid is the drug of choice to control the inflammation, and prevent the development of airway hyper responsiveness and later airway remodeling. House dust immunotherapy has been shown to be effective in patients with asthma, and also in those who do not respond well to standard drug therapy. Whether immunotherapy is as effective as inhaled corticosteroid need to be studied. The objective of this study is to investigate the ability of house dust immunotherapy to improve clinical index in children with asthma, and to compare its efficacy with inhaled corticosteroid. We evaluated the beneficial effect of house dust immunotherapy in 24 asthmatic children based on the value of FEV1 reversibility before and after treatment, and also compared its efficacy to the inhaled corticosteroid. All the patients were sensitive to house dust allergen. Twenty-four children (group I) treated with house-dust immunotherapy subcutaneously, once a week for 14 weeks, and group II treated with inhaled budesonide 100-200 μg once daily. The result of Wilcoxon Signed Rank Test showed there was a significant improvement between FEV1 reversibility test before and after house-dust immunotherapy (p=0.0001). Analysis with t-test also revealed that the efficacy of house dust immunotherapy did not differ from inhaled budesonide (p=0.872). In conclusion house dust immunotherapy has been shown to be as effective as inhaled corticosteroid in improving clinical outcome in the term of FEV1-reversibility in the treatment of childhood asthma.

Kata kunci

Jaringan kolaborasi para penulis

11 penulis · 18 tautan kepenulisan bersama

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Pudji LestariUniversitas Airlangga1
Retno AsihUniversitas Airlangga1
Florentina SustiniUniversitas Airlangga1
Natalia Erica JahjaUniversitas Airlangga1
Zahrah HikmahUniversitas Airlangga1
Azwin Mengindra PuteraUniversitas Airlangga1
Mira IrmawatiUniversitas Airlangga1
Ariyanto HarsonoAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">FEV1-Reversibility in House-Dust Immunotherapy Compared with Inhaled Corticosteroid in The Treatment of Childhood Asthma</dc:title><dc:creator>Arijanto Harsono</dc:creator><dc:creator>Lisa Angraini Subrata</dc:creator><dc:creator>Anang Endaryanto</dc:creator><dc:subject>inhaled corticosteroids</dc:subject><dc:subject>budesonide</dc:subject><dc:subject>childhood asthma</dc:subject><dc:subject>FEV1 reversibility</dc:subject><dc:subject>allergen sensitization</dc:subject><dc:subject>treatment efficacy comparison</dc:subject><dc:subject>subcutaneous immunotherapy</dc:subject><dc:description xml:lang="en">Asthma is a chronic inflammatory disease of the airway. Corticosteroid is the drug of choice to control the inflammation, and prevent the development of airway hyper responsiveness and later airway remodeling. House dust immunotherapy has been shown to be effective in patients with asthma, and also in those who do not respond well to standard drug therapy. Whether immunotherapy is as effective as inhaled corticosteroid need to be studied. The objective of this study is to investigate the ability of house dust immunotherapy to improve clinical index in children with asthma, and to compare its efficacy with inhaled corticosteroid. We evaluated the beneficial effect of house dust immunotherapy in 24 asthmatic children based on the value of FEV1 reversibility before and after treatment, and also compared its efficacy to the inhaled corticosteroid. All the patients were sensitive to house dust allergen. Twenty-four children (group I) treated with house-dust immunotherapy subcutaneously, once a week for 14 weeks, and group II treated with inhaled budesonide 100-200 μg once daily. The result of Wilcoxon Signed Rank Test showed there was a significant improvement between FEV1 reversibility test before and after house-dust immunotherapy (p=0.0001). Analysis with t-test also revealed that the efficacy of house dust immunotherapy did not differ from inhaled budesonide (p=0.872). In conclusion house dust immunotherapy has been shown to be as effective as inhaled corticosteroid in improving clinical outcome in the term of FEV1-reversibility in the treatment of childhood asthma.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2006-01-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>http://journal.unair.ac.id/download-fullpapers-08%20Ariyanto%20-%20FEV1.pdf</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 42 No 1 (2006)</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language></oai_dc:dc>